News

News

WIB_icon

A New Treatment Option for Patients with Severe von Willebrand Disease?

Treatment options to limit the risk of life-threatening bleeds associated with severe von Willebrand disease (vWD), a condition caused by a deficiency in or...

Clinical Trial Updates

A look at the ongoing clinical trials in multiple myeloma. PHASE III TRIALS A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo...
WIB_icon

Can Splanchnic Venous Thrombosis Predict Subsequent Cancer Diagnosis?

Research has shown that embolic events put patients at an increased risk for developing cancer: Venous thromboembolism (VTE) may represent a marker for occult...
WIB_icon

TIDEL-II: Individualized Approach to Imatinib Yields Promising Results

For patients with chronic-phase chronic myeloid leukemia (CPCML), a strategy of intensifying treatment with imatinib or selective switching to nilotinib based on molecular treatment targets leads to improved overall survival,...
WIB_icon

Examining Toxicity Profiles for Multiple Myeloma Regimens

Though treatment combinations such as melphalan, prednisone, and thalidomide (MPT-T) and melphalan, prednisone, and bortezomib (MPV) have improved survival in patients with multiple myeloma...

Viral History from a Single Drop of Blood, NCI Launches Gene Therapy Trial, FDA...

Going Viral: A New Test Detects Lifetime Virus Exposure with a Single Drop of Blood VirScan, a recently developed, high-throughput blood test, can detect nearly...
ASH Directions

Blood Journal’s Impact Factor, ASH Annual Meeting Abstract Submission Open, and more

Blood Journal’s Impact Factor the Highest Since 2010; First in Field of Hematology The Thomson Reuters’ Journal Citation Report®, released in June, revealed Blood’s impact...

Dormant Leukemia Cells May “Reawaken” During Late Relapse

Some patients deemed “cancer-free” can experience disease recurrence or relapse years after diagnosis and treatment, without any apparent cause. According to a paper published...

High Immunoglobulin E Levels: A Cause for Concern in Cancer Risk?

While it is common knowledge that immunoglobulin E (IgE) is produced by plasma cells as part of an allergic immune response, are plasma IgE...

For Perioperative Anticoagulation in Atrial Fibrillation: Burn Those Bridges

When patients with atrial fibrillation (AF) being treated with warfarin need to interrupt anticoagulation to undergo an elective operation or invasive procedure, the common...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.